$CERo Therapeutics (CERO.US)$CERo Therapeutics (CERO) shares surged 62%. The US Food and Drug Administration cleared the company's investigational new drug application for a phase 1 trial of its lead compound CER-1236 to treat acute myelogenous leukemia.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more